Acumen Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $27.00K.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $145.00K, a 291.89% increase year-over-year.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $2.00K.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $0.00.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $39.00K.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $325.00K, a 182.61% increase from fiscal 2022.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $115.00K, a 666.67% increase from fiscal 2021.
- Acumen Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $15.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $27.00K 10-Q · filed 2026-08-12 | $174.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $145.00K 10-Q · filed 2026-05-12 | $147.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $39.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | |
| 2025-03-31 | $37.00K 10-Q · filed 2026-05-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $325.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | $325.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $115.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $2.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $17.00K 10-Q · filed 2023-08-08 | |
| 2021-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $15.00K 10-K · filed 2023-03-27 |
| 2021-09-30 | $2.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |